Veloxis looks for next product
Craig Collard, CEO of Veloxis, consideres reaching for the company card to help find a new product that can further increase growth. "We are always looking at different things and we try to be very discriminating," he says.
Pharmaceutical company Veloxis has managed to turn its transplant drug Envarus into a money-making machine which is growing quickly, securing the company a USD 5.5 million profit in the last quarter.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
